Free Trial
NASDAQ:ACET

Adicet Bio (ACET) Stock Price, News & Analysis

Adicet Bio logo
$0.78 -0.02 (-2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 +0.01 (+1.69%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adicet Bio Stock (NASDAQ:ACET)

Key Stats

Today's Range
$0.76
$0.80
50-Day Range
$0.76
$1.09
52-Week Range
$0.74
$2.43
Volume
137,265 shs
Average Volume
854,888 shs
Market Capitalization
$64.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Moderate Buy

Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Remove Ads

Adicet Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

ACET MarketRank™: 

Adicet Bio scored higher than 68% of companies evaluated by MarketBeat, and ranked 327th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Adicet Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Adicet Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Adicet Bio are expected to decrease in the coming year, from ($1.39) to ($1.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adicet Bio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adicet Bio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adicet Bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Adicet Bio's valuation and earnings.
  • Percentage of Shares Shorted

    4.71% of the float of Adicet Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Adicet Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adicet Bio has recently decreased by 16.93%, indicating that investor sentiment is improving significantly.
  • Percentage of Shares Shorted

    4.71% of the float of Adicet Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Adicet Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adicet Bio has recently decreased by 16.93%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Adicet Bio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Adicet Bio this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adicet Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.10% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adicet Bio's insider trading history.
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Stock News Headlines

Truist Financial Reaffirms Their Buy Rating on Adicet Bio (ACET)
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
Adicet Bio reports Q4 EPS (32c), consensus (35c)
Adicet Bio files $250M mixed securities shelf
See More Headlines

ACET Stock Analysis - Frequently Asked Questions

Adicet Bio's stock was trading at $0.9620 on January 1st, 2025. Since then, ACET stock has decreased by 19.3% and is now trading at $0.7759.
View the best growth stocks for 2025 here
.

Adicet Bio, Inc. (NASDAQ:ACET) issued its quarterly earnings data on Thursday, March, 6th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05.

Top institutional investors of Adicet Bio include Tang Capital Management LLC (9.89%), Millennium Management LLC (2.20%), Bridgeway Capital Management LLC (1.25%) and Regeneron Pharmaceuticals Inc. (1.17%). Insiders that own company stock include Orbimed Advisors Llc, Don Healey, Francesco Galimi, Chen Schor, Blake Aftab and Steve Dubin.
View institutional ownership trends
.

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
3/06/2025
Today
3/13/2025
Next Earnings (Estimated)
3/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:ACET
CIK
2034
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+866.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-142,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Price / Cash Flow
N/A
Book Value
$2.43 per share
Price / Book
0.32

Miscellaneous

Free Float
66,662,000
Market Cap
$64.16 million
Optionable
Optionable
Beta
1.97

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ACET) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners